GENEVA, SWITZERLAND

February 15-16, 2014
LIVER CANCER MANAGEMENT
Clinical Programme:
February 13-14, 2014
IN LIVER CANCER
TRANSLATIONAL RESEARCH
Molecular Pathogenesis
Basic Programme:


EASL
European Association for the Study of the Liver

www.easle.eu/publications/2014
www.easle.eu/events/2014
www.easle.eu/hccsummit2014
METHODOLoGY: Patients with unresectable HCC for whom a decision to treat with sorafenib (SOF) was made after careful consideration of clinical data were followed up.

RESULTS: The greatest increase in tumor size occurred at 6 months, after which a decrease was observed. Treatment with SOF was associated with a significant decrease in tumor size compared to the baseline.

CONCLUSIONS: The safety profile of SOF in patients with unresectable HCC lesions is favorable, with no major adverse events reported. Treatment with SOF was associated with a significant decrease in tumor size compared to the baseline. However, further studies are needed to evaluate the long-term efficacy and safety of SOF in this patient population.

Corresponding author: email: [example@domain.com]

SOF improves OS, PFS, and QoL in patients with unresectable HCC. "The Global Institution of Therapeutic (TACE)"

Aims: The primary aim of the study was to evaluate the safety of sorafenib in HCC patients.

METHODOLoGY: Patients with unresectable HCC for whom a decision to treat with SOF was made after careful consideration of clinical data were followed up.

RESULTS: The greatest increase in tumor size occurred at 6 months, after which a decrease was observed. Treatment with SOF was associated with a significant decrease in tumor size compared to the baseline.

CONCLUSIONS: The safety profile of SOF in patients with unresectable HCC lesions is favorable, with no major adverse events reported. Treatment with SOF was associated with a significant decrease in tumor size compared to the baseline. However, further studies are needed to evaluate the long-term efficacy and safety of SOF in this patient population.

Corresponding author: email: [example@domain.com]